News on lab-developed tests and emerging diagnostic technologies.
The sites include Massachusetts General Hospital, Northwestern Medicine, Struthers Parkinson's Center, UC San Diego, and the Perelman School of Medicine.
The British molecular diagnostics company received a CE-IVD mark for the assay, called BCA-1, in June, and launched the test in October.
Researchers at Baylor College of Medicine and Columbia University found that almost all blood samples from pregnant women tested contained several trophoblasts.
In a proof-of-principle study, Ohio State University researchers compared the nanopore sequencing assay to short-read sequencing and capillary electrophoresis.
The firm also said it is contemplating selling its therapeutics division, and appointed David Bench as its new CFO.
